Comparison between obese and non-obese nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions that are characterized by excess accumulation of fat in the liver, and is diagnosed after exclusion of significant alcohol intake and other causes of chronic liver disease. In the majority of cases, NAFLD is associat...

Full description

Bibliographic Details
Main Author: Wah-Kheong Chan
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2023-02-01
Series:Clinical and Molecular Hepatology
Subjects:
Online Access:http://e-cmh.org/upload/pdf/cmh-2022-0350.pdf
_version_ 1797871486783979520
author Wah-Kheong Chan
author_facet Wah-Kheong Chan
author_sort Wah-Kheong Chan
collection DOAJ
description Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions that are characterized by excess accumulation of fat in the liver, and is diagnosed after exclusion of significant alcohol intake and other causes of chronic liver disease. In the majority of cases, NAFLD is associated with overnutrition and obesity, although it may be also found in lean or non-obese individuals. It has been estimated that 19.2% of NAFLD patients are lean and 40.8% are non-obese. The proportion of patients with more severe liver disease and the incidence of all-cause mortality, liver-related mortality, and cardiovascular mortality among non-obese and obese NAFLD patients varies across studies and may be confounded by selection bias, underestimation of alcohol intake, and unaccounted weight changes over time. Genetic factors may have a greater effect towards the development of NAFLD in lean or non-obese individuals, but the effect may be less pronounced in the presence of strong environmental factors, such as poor dietary choices and a sedentary lifestyle, as body mass index increases in the obese state. Overall, non-invasive tests, such as the Fibrosis-4 index, NAFLD fibrosis score, and liver stiffness measurement, perform better in lean or non-obese patients compared to obese patients. Lifestyle intervention works in non-obese patients, and less amount of weight loss may be required to achieve similar results compared to obese patients. Pharmacological therapy in non-obese NAFLD patients may require special consideration and a different approach compared to obese patients.
first_indexed 2024-04-10T00:44:41Z
format Article
id doaj.art-186279c3758a4d9e8e284128920de9d6
institution Directory Open Access Journal
issn 2287-2728
2287-285X
language English
last_indexed 2024-04-10T00:44:41Z
publishDate 2023-02-01
publisher Korean Association for the Study of the Liver
record_format Article
series Clinical and Molecular Hepatology
spelling doaj.art-186279c3758a4d9e8e284128920de9d62023-03-14T01:46:51ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2023-02-0129SupplS58S6710.3350/cmh.2022.03501739Comparison between obese and non-obese nonalcoholic fatty liver diseaseWah-Kheong ChanNonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions that are characterized by excess accumulation of fat in the liver, and is diagnosed after exclusion of significant alcohol intake and other causes of chronic liver disease. In the majority of cases, NAFLD is associated with overnutrition and obesity, although it may be also found in lean or non-obese individuals. It has been estimated that 19.2% of NAFLD patients are lean and 40.8% are non-obese. The proportion of patients with more severe liver disease and the incidence of all-cause mortality, liver-related mortality, and cardiovascular mortality among non-obese and obese NAFLD patients varies across studies and may be confounded by selection bias, underestimation of alcohol intake, and unaccounted weight changes over time. Genetic factors may have a greater effect towards the development of NAFLD in lean or non-obese individuals, but the effect may be less pronounced in the presence of strong environmental factors, such as poor dietary choices and a sedentary lifestyle, as body mass index increases in the obese state. Overall, non-invasive tests, such as the Fibrosis-4 index, NAFLD fibrosis score, and liver stiffness measurement, perform better in lean or non-obese patients compared to obese patients. Lifestyle intervention works in non-obese patients, and less amount of weight loss may be required to achieve similar results compared to obese patients. Pharmacological therapy in non-obese NAFLD patients may require special consideration and a different approach compared to obese patients.http://e-cmh.org/upload/pdf/cmh-2022-0350.pdfnonalcoholic fatty liver diseasenon-obeselean
spellingShingle Wah-Kheong Chan
Comparison between obese and non-obese nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
nonalcoholic fatty liver disease
non-obese
lean
title Comparison between obese and non-obese nonalcoholic fatty liver disease
title_full Comparison between obese and non-obese nonalcoholic fatty liver disease
title_fullStr Comparison between obese and non-obese nonalcoholic fatty liver disease
title_full_unstemmed Comparison between obese and non-obese nonalcoholic fatty liver disease
title_short Comparison between obese and non-obese nonalcoholic fatty liver disease
title_sort comparison between obese and non obese nonalcoholic fatty liver disease
topic nonalcoholic fatty liver disease
non-obese
lean
url http://e-cmh.org/upload/pdf/cmh-2022-0350.pdf
work_keys_str_mv AT wahkheongchan comparisonbetweenobeseandnonobesenonalcoholicfattyliverdisease